QuidelOrtho Corp (NASDAQ:QDEL) reported an insider purchase by Chief Financial Officer Joseph M. Busky, who acquired 3,370 shares of common stock on February 13, 2026, at $23.6623 per share. The transaction totaled approximately $79,741, according to a Form 4 filing with the Securities and Exchange Commission.
Following the purchase, Busky directly holds 41,412 shares of QuidelOrtho and has an indirect holding of 10,290 shares through a trust. The buy comes as the company’s share price has suffered notable declines, falling 18.4% over the past week and 43% year-over-year, and is trading near its 52-week low of $19.50.
The company carries a market capitalization of $1.62 billion and is described as operating with a significant debt burden. In parallel, analysis from InvestingPro cited in the filing indicates net income is expected to grow during the current year. QuidelOrtho was not profitable over the last twelve months, and analysts predict the company will return to profitability in 2026.
The firm's fourth-quarter 2025 financials presented a mixed picture. QuidelOrtho reported revenue of $724 million, ahead of the $701 million analysts had forecast, representing a 3.28% positive revenue surprise. On the other hand, adjusted earnings per share were $0.46, missing expectations of $0.51 and marking a 9.8% negative surprise. The revenue beat and EPS miss together underline the uneven nature of the company’s recent performance.
Summary
- QuidelOrtho CFO Joseph M. Busky bought 3,370 shares on February 13, 2026, for about $79,741.
- After the trade, Busky directly owns 41,412 shares and indirectly holds 10,290 shares via trust.
- The stock has declined 18.4% over the past week and 43% year-over-year, trading near a 52-week low of $19.50.
Key points
- Insider activity: A senior financial officer increased his stake through a direct purchase reported on a Form 4 filing.
- Market performance: Shares are trading near their 52-week low after recent steep declines.
- Financial results: Q4 2025 revenue beat expectations while adjusted EPS fell short of estimates, reflecting mixed quarterly results that matter to investors and the healthcare-equipment and diagnostics sectors.
Risks and uncertainties
- Leverage: The company operates with a significant debt burden that could affect financial flexibility and credit-sensitive costs.
- Profitability timeline: QuidelOrtho was not profitable over the last twelve months, and while analysts expect a return to profitability in 2026, that outcome remains a forecast rather than a realized result.
- Share-price volatility: Recent steep declines and trading near the 52-week low introduce market risk for shareholders and potential investors.
These items together frame the recent insider purchase alongside the company's current financial profile and recent operating results.